cancer for administration to a human female subject comprising selecting an agent based on its

ability to upregulate TGF-β expression in the ovarian epithelium by testing said agent by treating

ovarian epithelial cells through exposure to said agent and determining the resulting expression

of TGF-β in the treated ovarian epithelial cells.

2.   The method of claim 1 wherein said agent is a progestin product.

3.   The method of claim 2 wherein said ovarian epithelial cells are treated

with said agent using an *in vivo* test.

4.   The method of claim 2 wherein said test is conducted *in vitro*.

5.   The method of claim 2 wherein said measured TGF-β expression is

upregulation of TGF-β 2 or TGF-β 3.

6.   The method of claim 5 further comprising formulating a regimen wherein

said regimen comprises a daily dosage of said composition for use by human female subject.

MARKED CLAIMS:

1.   (Amended) A method of formulating a [regimen] composition for

preventing epithelial ovarian cancer for administration to a human female subject comprising

selecting an agent based on its ability to upregulate TGF-β expression in the ovarian epithelium

by testing said agent by treating ovarian epithelial cells through exposure to said agent and

determining the resulting expression of TGF-β in the treated ovarian epithelial cells.

3. (New)   The method of claim 2 wherein said ovarian epithelial cells are

treated with said agent using an *in vivo* test.--

4. (New)   The method of claim 2 wherein said test is conducted *in vitro*.

5. (New)   The method of claim 2 wherein said measured TGF-β expression is

2